24,486 Shares in Encompass Health Corporation $EHC Bought by Man Group plc

Man Group plc purchased a new stake in Encompass Health Corporation (NYSE:EHC) in the second quarter, HoldingsChannel reports. The fund purchased 24,486 shares of the company’s stock, valued at approximately $2,475,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Persistent Asset Partners Ltd acquired a new position in shares of Encompass Health during the second quarter valued at about $36,000. Keating Financial Advisory Services Inc. bought a new position in Encompass Health during the second quarter valued at about $39,000. Assetmark Inc. increased its stake in Encompass Health by 89.6% during the first quarter. Assetmark Inc. now owns 455 shares of the company’s stock valued at $44,000 after acquiring an additional 215 shares during the period. Caitong International Asset Management Co. Ltd raised its holdings in Encompass Health by 36,200.0% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 363 shares of the company’s stock valued at $46,000 after acquiring an additional 362 shares in the last quarter. Finally, Aster Capital Management DIFC Ltd bought a new stake in shares of Encompass Health in the 4th quarter worth approximately $55,000. Institutional investors own 97.25% of the company’s stock.

Encompass Health Stock Performance

Shares of NYSE:EHC opened at $120.51 on Tuesday. The company has a debt-to-equity ratio of 0.76, a current ratio of 1.19 and a quick ratio of 1.19. The business’s fifty day moving average price is $113.64 and its two-hundred day moving average price is $107.27. Encompass Health Corporation has a fifty-two week low of $92.77 and a fifty-two week high of $127.99. The stock has a market capitalization of $11.89 billion, a price-to-earnings ratio of 19.63, a price-to-earnings-growth ratio of 2.45 and a beta of 0.72.

Encompass Health (NYSE:EHC) last issued its earnings results on Wednesday, August 5th. The company reported $1.55 EPS for the quarter, beating the consensus estimate of $1.48 by $0.07. Encompass Health had a net margin of 10.01% and a return on equity of 18.08%. The company had revenue of $1.60 billion for the quarter, compared to the consensus estimate of $1.57 billion. During the same quarter in the previous year, the company earned $1.40 EPS. The firm’s revenue for the quarter was up 9.6% compared to the same quarter last year. Encompass Health has set its FY 2026 guidance at 6.020-6.250 EPS. As a group, analysts predict that Encompass Health Corporation will post 6.08 EPS for the current fiscal year.

Encompass Health Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, October 15th. Stockholders of record on Thursday, October 1st will be paid a $0.21 dividend. This represents a $0.84 dividend on an annualized basis and a dividend yield of 0.7%. This is an increase from Encompass Health’s previous quarterly dividend of $0.19. The ex-dividend date is Thursday, October 1st. Encompass Health’s dividend payout ratio is presently 12.38%.

Insider Activity at Encompass Health

In related news, EVP John Patrick Darby sold 8,906 shares of the stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $125.95, for a total transaction of $1,121,710.70. Following the sale, the executive vice president directly owned 75,041 shares in the company, valued at $9,451,413.95. This represents a 10.61% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Mark J. Tarr sold 173,148 shares of the business’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $125.47, for a total value of $21,724,879.56. Following the completion of the transaction, the chief executive officer directly owned 267,814 shares in the company, valued at approximately $33,602,622.58. This represents a 39.27% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 1.80% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of research firms have recently issued reports on EHC. UBS Group boosted their price objective on Encompass Health from $150.00 to $155.00 and gave the company a “buy” rating in a research report on Friday, August 7th. Weiss Ratings upgraded shares of Encompass Health from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday, August 12th. Truist Financial boosted their price target on shares of Encompass Health from $140.00 to $150.00 and gave the company a “buy” rating in a report on Friday, August 7th. Barclays increased their price objective on shares of Encompass Health from $140.00 to $144.00 and gave the company an “overweight” rating in a research note on Thursday, August 6th. Finally, Leerink Partners set a $152.00 target price on shares of Encompass Health in a research report on Friday, May 22nd. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has given a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $148.71.

Encompass Health Company Profile

Encompass Health Corporation is a leading provider of post‐acute healthcare services in the United States, operating a comprehensive network of inpatient rehabilitation hospitals and home health and hospice agencies. Its inpatient rehabilitation hospitals offer intensive therapy programs for patients recovering from conditions such as stroke, brain injury, spinal cord injury, cardiac and pulmonary disorders, and orthopedic procedures. Through its home health segment, Encompass Health delivers skilled nursing, physical therapy, occupational therapy and speech therapy to patients in the comfort of their homes, while its hospice services provide end‐of‐life care focused on symptom management and emotional support for patients and families.

Founded in 1984 as HealthSouth Corporation and rebranded as Encompass Health in 2018, the company has grown organically and through acquisitions to serve patients across more than 30 states.